GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » Tax Expense

AXIM (AXIM Biotechnologies) Tax Expense : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies Tax Expense?

AXIM Biotechnologies's tax expense for the months ended in Jun. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.


AXIM Biotechnologies Tax Expense Historical Data

The historical data trend for AXIM Biotechnologies's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies Tax Expense Chart

AXIM Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AXIM Biotechnologies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AXIM Biotechnologies Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AXIM Biotechnologies  (OTCPK:AXIM) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


AXIM Biotechnologies Tax Expense Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


AXIM Biotechnologies Business Description

Traded in Other Exchanges
N/A
Address
6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.
Executives
Kurt Phinney officer: Chief Operating Officer 6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke director C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp 10 percent owner 5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii director 305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek officer: CFO PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc. 10 percent owner 12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022

AXIM Biotechnologies Headlines